Clinical trials: Watch & Wait
Hepatocellular Carcinoma
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Some people with HCC have no visible active tumor on imaging after receiving anticancer treatment.
- Trial name
- SWITCH-R (NCT07866612)
- Testing
- Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Rectal Cancer
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design…
- Trial name
- NCT04443543
- Testing
- Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Fudan University
Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general…
- Conditions
- Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer, Microsatellite Instability-High Colorectal Cancer, Stage II Colorectal Cancer
- Trial name
- RESIST (NCT07829081)
- Testing
- Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care
- Where
- 3 sites in Switzerland
- Volunteers
- 234 people
- Sponsor
- University Hospital, Basel, Switzerland
Randomized, Phase 2
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.
- Conditions
- Randomized, Phase 2, Epcoritamab, Watch & Wait
- Trial name
- NCT07783594
- Testing
- Epcoritamab, Observation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Rectum Cancer
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
Aim: To investigate the safety and efficacy of organ preservation (OP) with watch-and-wait strategy (W\&W) or local excision (LE) in MRI stratified low-risk rectal cancer treated by total neoadjuvant treatment.
- Trial name
- BJCC-R01 (NCT04405206)
- Testing
- Oxaliplatin, Capecitabine, intensity modulated radiotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer, Colorectal Cancer
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
The purpose of this study is to demonstrate the functionality of a novel endorectal photoacoustic ultrasound imaging modality in humans with rectal cancer.
- Trial name
- NCT04339374
- Testing
- Photoacoustic imaging, photoacoustic microscopy, Endorectal photoacoustic imaging probe, Reader Performance
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Rectal Neoplasms, Rectal Cancer
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative…
- Trial name
- NCT04095468
- Testing
- Preoperative Radio(Chemo)Therapy
- Where
- 7 sites in Poland
- Volunteers
- 215 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Rectal Cancer, Comorbidities and Coexisting Conditions
Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy
Within our institution, the principal investigator have acquired expertise in endorectal brachytherapy, a localized treatment for colorectal cancer.
- Conditions
- Rectal Cancer, Comorbidities and Coexisting Conditions, Inoperable Disease, Brachytherapy
- Trial name
- Whistle (NCT04336202)
- Testing
- External beam radiotherapy + Endorectal brachytherapy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Rectal Neoplasms
"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer
The aim of this prospective observational cohort study is to provide short and long term oncological and functional outcome data on organ preserving treatment in good responders after a standard indication for neoadjuvant…
- Trial name
- NCT03426397
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 220 people
- Sponsor
- The Netherlands Cancer Institute
Cancer of the Rectum
The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
The primary objectives of this study are to determine if the inclusion of ctDNA testing in the evaluation and management of stages 2 and 3 rectal cancers will allow clinicians to improve their selection of patients for wait and…
- Trial name
- SNOWW (NCT07292285)
- Sponsor
- University of Colorado, Denver
Adenocarcinoma - GEJ, Gastric Adenocarcinoma
DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study
This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- DEWI (NCT06059495)
- Testing
- Dostarlimab
- Where
- 18 sites in France, Italy
- Volunteers
- 89 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Cancer
"Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
Among patients treated for locally advanced rectal cancer with neo-adjuvant radio-chemotherapy, about 15% will have complete clinical response in terms of no visible tumor or ulcerations on the site of the primary tumor, or…
- Trial name
- NORWAIT (NCT03402477)
- Where
- 7 sites in Norway
- Volunteers
- 86 people
- Sponsor
- Helse Stavanger HF
Colon Cancer
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.
The goal of this investigational, multicenter, open-label randomized, two-stage phase II study is to evaluate neoadjuvant pembrolizumab with a watch-and-wait approach in patients with localized deficient mismatch repair / high…
- Trial name
- PREMICES (NCT06646445)
- Testing
- Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery
- Where
- 10 sites in France
- Volunteers
- 60 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
DMMR Colorectal Cancer, Colon Cancer Stage I
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
The RESET C2 trial aims to introduce organ sparing treatment or watch-and-wait (WW) to patients with localized deficient mismatch repair (dMMR) colon cancer through use of neoadjuvant pembrolizumab.
- Conditions
- DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab
- Trial name
- RESET C2 (NCT07409844)
- Testing
- 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab
- Where
- Denmark
- Volunteers
- 152 people
- Sponsor
- Ismail Gögenur
Rectal Cancer, Consolidation
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
Background: Neoadjuvant chemoradiation (nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer.
- Trial name
- CCHOWW (NCT05000697)
- Testing
- Oxaliplatin, 5FU
- Where
- 24 sites in Argentina, Brazil and 1 more
- Volunteers
- 216 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Hepatocellular Carcinoma
Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancers and is the sixth most common cancer in the world and ranked third in mortality.
- Trial name
- WATCH (NCT05349331)
- Testing
- Liver Resection
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer
This study evaluates whether mesorectal chemoradiotherapy with a limited radiation target volume can achieve a sustained clinical complete response in patients with early-stage rectal cancer, allowing surgery to be safely…
- Trial name
- NG-ST (NCT07483060)
- Testing
- Capecitabine + Radiotherapy, Total Mesorectal Excision (TME)
- Volunteers
- 90 people
- Sponsor
- Vastra Gotaland Region
Locally Advanced Rectal Cancer (LARC)
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation…
- Trial name
- NCT04009876
- Testing
- nal-IRI, Surgical resection, Watch-and-wait
- Where
- 4 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Rectal Cancer, Chemoradiotherapy
Non-OpeRative MANagement of Rectal Cancer Patients
This study is a single-center, open, prospective, single-treatment trial (pilot study). This study aims to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for 4 months after non-surgical treatment…
- Conditions
- Rectal Cancer, Chemoradiotherapy, Watch & Wait
- Trial name
- NORMANDY (NCT04696757)
- Testing
- Capecitabine
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Kangbuk Samsung Hospital
Rectal Adenocarcinoma, Rectal Cancer
Asian Watch-and-Wait Database (AWWD)
The standard treatment approach of localized rectal adenocarcinoma involves neoadjuvant radiotherapy and chemotherapy followed by assessment for surgery and optional adjuvant chemotherapy.
- Trial name
- AWWD (NCT06631443)
- Where
- India
- Volunteers
- 337 people
- Sponsor
- Tata Memorial Centre